Related Experiment Video
Updated: Jan 10, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Elevated Transaminases: Does It Always Warrant a Liver Biopsy? Lessons Learned From Pompe Disease
Alicia Khazzeka1, Rebecca L Koch1, Jeong-A Lim1
1Division of Medical Genetics, Department of Pediatrics Duke University School of Medicine Durham North Carolina USA.
Insights
Pompe disease (PD) diagnosis can be challenging due to elevated transaminases mimicking liver issues. This study emphasizes considering muscle origin, indicated by AST:ALT > 1 and elevated CK, to avoid unnecessary liver biopsies in late-onset PD patients.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Pompe disease (PD) is an inherited metabolic disorder caused by acid alpha-glucosidase (GAA) deficiency.
- Late-onset PD (LOPD) often presents with elevated transaminases, mimicking liver disease and potentially leading to misdiagnosis.
- Elevated transaminases in LOPD reflect muscle injury, not hepatic damage.
Purpose of the Study:
- To highlight the diagnostic challenges in late-onset Pompe disease (LOPD).
- To emphasize the importance of differentiating muscle injury from liver disease in LOPD diagnosis.
- To underscore the value of specific clinical and biochemical markers in guiding LOPD diagnosis and avoiding invasive procedures.
Main Methods:
- Review of three LOPD patient cases with elevated transaminases who underwent liver biopsies prior to diagnosis.
- Evaluation of liver histology and comparison with a GAA knockout mouse model.
- Analysis of clinical presentations, diagnostic workups, enzyme testing, and genetic testing for GAA variants.
Main Results:
- All reviewed cases had elevated transaminases and underwent liver biopsy, with findings ranging from normal to non-specific glycogen accumulation.
- Aspartate transaminase (AST) levels were higher than alanine transaminase (ALT) levels (AST:ALT > 1) in all cases, with elevated creatine kinase (CK).
- Enzyme and genetic testing confirmed GAA deficiency and pathogenic GAA variants, establishing the LOPD diagnosis.
Conclusions:
- Elevated transaminases in LOPD warrant consideration of a muscle origin, especially when AST:ALT > 1 and CK is elevated.
- Liver biopsy is often unnecessary and can be misleading in LOPD diagnosis.
- Non-invasive approaches like neuromuscular gene panels and GAA enzyme testing are crucial for accurate LOPD diagnosis.
Abstract:
Pompe disease (PD) is an autosomal recessive disorder caused by pathogenic variants in GAA, resulting in acid alpha-glucosidase (GAA) deficiency and lysosomal glycogen accumulation. PD is classified into infantile-onset (IOPD), characterized by cardiomyopathy and death within the first year if untreated, and late-onset (LOPD), which presents with gradual muscle weakness at variable ages. Incidentally elevated transaminase levels are common in LOPD and reflect muscle injury rather than liver damage. Creatine kinase (CK) levels are often elevated too, further indicating a myopathic origin. However, these elevated transaminases may be misattributed to liver disease, prompting a liver biopsy. Three charts of patients who underwent liver biopsies prior to a LOPD diagnosis were reviewed, including clinical presentations and diagnostic workups. Liver histology from these biopsies was evaluated and compared to liver pathology in a GAA knockout mouse model. All cases had elevated transaminases and underwent a liver biopsy. One biopsy was normal, while two showed non-specific hepatocyte glycogen accumulation. In all cases, aspartate transaminase (AST) levels were higher than alanine transaminase (ALT) levels and CK levels were elevated. Enzyme testing demonstrated GAA deficiency, and genetic testing identified biallelic variants in GAA, confirming the diagnosis. These cases highlight the importance of meticulous phenotyping before liver biopsy. A muscle origin should be considered when AST:ALT > 1 with elevated CK levels. Neuromuscular gene panels and GAA enzyme testing offer a non-invasive diagnostic approach in LOPD. Notably, even when glycogen accumulation is observed in the liver histologically, liver disease is not associated with PD.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
07:10Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Assessment:
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Lysosomal Hydrolases